Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions
BACKGROUND Human papillomavirus types 16 (HPV-16) and 18 (HPV-18) cause approximately 70% of cervical cancers worldwide. A phase 3 trial was conducted to evaluate a quadrivalent vaccine against HPV types 6, 11, 16, and 18 (HPV-6/11/16/18) for the prevention of high-grade cervical lesions associated...
Autor Principal: | |
---|---|
Formato: | Artículo (Article) |
Lenguaje: | Inglés (English) |
Publicado: |
Massachusetts Medical Society
2007
|
Materias: | |
Acceso en línea: | https://repository.urosario.edu.co/handle/10336/26826 https://doi.org/10.1056/NEJMoa061741 |